Royalty Pharma (RPRX) Treasury Shares (2019 - 2026)
Royalty Pharma (RPRX) posted Treasury Shares of $2.7 million for Q1 2026, up 3.71% sequentially from $2.6 million in Q4 2025, and up 2.07% YoY from $2.7 million in Q1 2025.
Royalty Pharma (RPRX) Treasury Shares (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Treasury Shares for 2 years, with the latest figure at $18.4 million in Q1 2026.
- Quarterly Treasury Shares rose 2.07% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (up 2.07% YoY) and the FY2025 annual result came in at $2.6 million, down 1.88% from the prior year.
- Treasury Shares rose to $2.7 million in Q1 2026 per RPRX's latest filing, from $2.6 million in the prior quarter.
- Over five years, Treasury Shares peaked at $2.8 million in Q1 2023 and troughed at $2.6 million in Q3 2025.
- A 5-year average of $2.7 million and a median of $2.7 million in 2024 frame the typical range for Treasury Shares.
- The sharpest annual moves came in 2022 and 2023: Treasury Shares climbed 15.98% in 2022, then dropped 6.31% in 2023.
- Over 5 years, Treasury Shares stood at $2.8 million in 2022, then dropped by 6.31% to $2.6 million in 2023, then gained by 1.26% to $2.7 million in 2024, then slipped by 1.88% to $2.6 million in 2025, then grew by 3.71% to $2.7 million in 2026.
- According to Business Quant data, Treasury Shares over the past three periods registered $2.7 million, $2.6 million, and $2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 48.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.72 Mn |
| Jun 30, 2026 | 2.72 Mn |
| Jun 30, 2026 | 17.20 Mn |
| Jun 30, 2026 | 17.20 Mn |
| Mar 31, 2026 | 18.40 Mn |
| Mar 31, 2026 | 18.40 Mn |
| Mar 31, 2026 | 2.71 Mn |
| Mar 31, 2026 | 2.71 Mn |
| Dec 31, 2025 | 19.50 Mn |
| Dec 31, 2025 | 19.50 Mn |
| Dec 31, 2025 | 2.61 Mn |
| Dec 31, 2025 | 2.61 Mn |
| Sep 30, 2025 | 2.61 Mn |
| Sep 30, 2025 | 2.61 Mn |
| Sep 30, 2025 | 20.50 Mn |
| Sep 30, 2025 | 20.50 Mn |
| Jun 30, 2025 | 21.50 Mn |
| Jun 30, 2025 | 21.50 Mn |
| Jun 30, 2025 | 2.61 Mn |
| Jun 30, 2025 | 2.61 Mn |